http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Merus N.V. (MRUS) Appoints Fabian Zohren M.D., Ph.D., as Chief Medical Officer
-
Merus Appoints Fabian Zohren M.D., Ph.D., as Chief Medical Officer
-
Merus' (MRUS) Petosemtamab in Combination with Pembrolizumab Interim Data Demonstrates Robust Response Rate and Favorable Safety Profile in 1L r/m HNSCC
-
Merus’ Petosemtamab in Combination with Pembrolizumab Interim Data Demonstrates Robust Response Rate and Favorable Safety Profile in 1L r/m HNSCC
-
Merus (MRUS) Announces Publication of an Abstract on Petosemtamab with Pembrolizumab as 1L treatment of r/m HNSCC at the 2024 ASCO Annual Meeting
-
Merus Announces Publication of an Abstract on Petosemtamab with Pembrolizumab as 1L treatment of r/m HNSCC at the 2024 ASCO® Annual Meeting
-
Merus Announces Publication of Abstracts for Presentation at the 2024 ASCO® Annual Meeting
-
Merus N.V. (MRUS) Reports Petosemtamab Granted FDA Breakthrough Therapy Designation
-
Petosemtamab granted Breakthrough Therapy Designation by the U.S. FDA
-
Gilead Sciences (GILD), Merus (MRUS) Announce Collaboration to Discover Novel Antibody-Based Trispecific T-Cell Engagers
-
Gilead and Merus Announce Collaboration to Discover Novel Antibody-Based Trispecific T-Cell Engagers
-
Merus to Participate in Upcoming Investor Conferences
-
Merus Presents Interim Data on MCLA-129 at ESMO Asia Congress 2023
-
Merus Announces Publication of Abstracts on MCLA-129 for Presentation at ESMO Asia Congress 2023
-
Merus Announces Financial Results for the Third Quarter 2023 and Provides Business Update
-
Merus to Participate in Upcoming Investor Conferences
-
Merus’ Zeno Interim Data Continues to Demonstrate Robust and Durable Responses in NRG1+ Cancer
-
Merus Announces Business Update Conference Call
-
Merus Announces Abstracts Accepted for Presentation at the ESMO Asia Congress 2023
-
Merus to Participate in Upcoming Investor Conferences
-
Merus Announces Financial Results for the Second Quarter 2023 and Provides Business Update
-
Merus Announces Two Clinical Abstracts on Zenocutuzumab (Zeno) in NRG1-fusion (NRG1+) non-small cell lung cancer (NSCLC) and Pancreatic Cancer (PDAC) Selected for Presentation at the ESMO Congress 202
-
Merus N.V. (MRUS) Announces Zenocutuzumab (Zeno) granted second Breakthrough Therapy Designation by FDA
-
Zenocutuzumab (Zeno) granted second Breakthrough Therapy Designation by the U.S. Food & Drug Administration
-
Zenocutuzumab (Zeno) granted second Breakthrough Therapy Designation by the U.S. Food & Drug Administration
-
Merus N.V. (MRUS) Reports Zenocutuzumab granted Breakthrough Therapy Designation by FDA
-
Zenocutuzumab (Zeno) granted Breakthrough Therapy Designation by the U.S. Food & Drug Administration for the treatment of NRG1+ pancreatic cancer
-
Zenocutuzumab (Zeno) granted Breakthrough Therapy Designation by the U.S. Food & Drug Administration for the treatment of NRG1+ pancreatic cancer
-
Merus N.V. (MRUS) Appoints Greg Perry as CFO
-
Merus Appoints Life Sciences Strategic and Financial Industry Veteran Greg Perry as Chief Financial Officer
-
Merus to Participate in a Fireside Chat at the Jefferies Healthcare Conference 2023
-
Merus Announces Financial Results for the First Quarter 2023 and Provides Business Update
-
Merus N.V. (MRUS) Petosemtamab Interim Data Demonstrates Clinically Meaningful Activity in Previously Treated Head and Neck Squamous Cell Carcinoma
-
Merus’ Petosemtamab Interim Data Demonstrates Clinically Meaningful Activity in Previously Treated Head and Neck Squamous Cell Carcinoma (HNSCC)
-
Merus’ Petosemtamab Interim Data Demonstrates Clinically Meaningful Activity in Previously Treated Head and Neck Squamous Cell Carcinoma (HNSCC)
-
Merus N.V. (MRUS) Announces Publication of an Abstract on Petosemtamab Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma for Plenary Session Oral Presentation at the AACR
-
Merus N.V. (MRUS) Announces Publication of an Abstract on Petosemtamab in Advanced Gastric/Esophageal Adenocarcinoma for Presentation at the AACR
-
Merus Announces Publication of an Abstract on Petosemtamab in Advanced Gastric/Esophageal Adenocarcinoma for Presentation at the AACR Annual Meeting 2023
-
Merus Announces Publication of an Abstract on Petosemtamab Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma for Plenary Session Oral Presentation at the AACR Annual Meeting 2023
-
Merus Announces Publication of an Abstract on Petosemtamab Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma for Plenary Session Oral Presentation at the AACR Annual Meeting 2023
-
Merus Announces Publication of an Abstract on Petosemtamab in Advanced Gastric/Esophageal Adenocarcinoma for Presentation at the AACR Annual Meeting 2023
-
Merus Announces Publication of an Abstract on Preclinical Mechanism of Action of MCLA-129 Selected for Poster Presentation at the AACR Annual Meeting 2023
-
Merus Announces Petosemtamab in Previously Treated Head and Neck Squamous Cell Carcinoma Abstract Selected for Plenary Session Oral Presentation at the AACR Annual Meeting 2023
-
Merus Announces Publication of an Abstract on Preclinical Mechanism of Action of MCLA-129 Selected for Poster Presentation at the AACR Annual Meeting 2023
-
Merus Announces Petosemtamab in Previously Treated Head and Neck Squamous Cell Carcinoma Abstract Selected for Plenary Session Oral Presentation at the AACR Annual Meeting 2023
-
Merus Announces Financial Results for the Fourth Quarter and Full Year 2022 and Provides Business Update
-
Merus Announces Financial Results for the Fourth Quarter and Full Year 2022 and Provides Business Update
-
Merus to Participate in Upcoming Investor Conferences
-
Merus to Participate in Upcoming Investor Conferences
-
CORRECTING and REPLACING --Merus Provides 2023 Outlook
